The use of biological variables to predict outcome in multiple myeloma

British Journal of Haematology

Volumn 99, Issue 4, 1997, Pages 719-725

  Davies, F E ^a   Jack, A S ^a   Morgan, G J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Biological variables; Multiple myeloma; Prognosis

Indexed keywords

ANTIBODY; BETA1 INTEGRIN; CD19 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; DNA; HERMES ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NERVE CELL ADHESION MOLECULE; SYNDECAN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 5;

CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; DNA CONTENT; FLOW CYTOMETRY; GENE; GENE MUTATION; HEMATOPOIETIC SYSTEM; HISTORY; HUMAN; MOLECULAR GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; PHENOTYPE; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0031470497     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3793193.x     Document Type: Review

References (69)

1. Abildgaard, N., Bentzen, S.M., Nielson, J.L. & Heickenddorff, L. (1997) Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type 1 collagen (ITCP). British Journal of Haematology, 96, 103-110.
2. Alsina, M., Boyce, B., Devlin, R.D., Anderson, J.L., Craig, F., Mundy, G. & Roodman, G.D. (1996) Development of an in vivo model of human multiple myeloma bone disease. Blood, 87, 1495-1501.
3. Bakkus, M.H.C., Van Riet, I., Van Camp, B. & Thielemans, K. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pe-switched but somatically mutated B cell. British Journal of Haematology, 87, 68-74.
4. Bataille, R., Chappard, D. & Basle, M.F. (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood. 87, 4762-4769.
5. Bataille, R., Chappard, D. & Klein, B. (1992) Mechanisms of bone lesions in multiple myeloma. Hematology and Oncology Clinics of North America, 6, 285-295.
6. Bataille, R., Delmas, P.D., Chappard. D., & Sany, J. (1990) Abnormal serum bone gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer. 66, 167-172.
7. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical investigation, 84, 2008-2011.
8. Berenson, J., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 8 488-493.
9. + peripheral blood cells expressing CD38. CD56 and monotypic Ig light chain. Blood. 85, 436-447.
10. Brown, R.D., Pope, B., Luo, X.F., Gibson, J. & Joshua, D. (1994) The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leukaemia and Lymphoma, 16, 147-156.
11. Chen, B.J. & Epstein, J. (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood, 87, 1972-1976.
12. Chesi, M., Bergsagel, P.L., Brents, L.A., Smith, C.M., Gerhard, D.S. & Kuehl, W.M. (1996) Dysregulation of cyclin D1 by translocation into the IgH gamma switch region in two multiple myeloma cell lines. Blood. 88, 674-681.
13. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. & Bergsagel, P.L. (1997) Frequent translocation t(4:14)(p16.3:q32.3) in multiple myeloma: association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics, in press.
14. Corrdini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D., Boccadoro, M., Pileri, A. & Dalla-Favera, R. (1994) Inactivation of tumour suppressor genes. p53 and Rb1, in plasma cell dyscrasias. Leukaemia. 8, 758-767.
15. Corrdini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D., Boccadoro, M. & Pileri, A. (1993) Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81, 2708-2713.
16. Degrassi, A., Hilbert, D.M., Rudikoff, S., Anderson, A., Potter, M. & Coon, H.G. (1993) In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proceedings of the National Academy of Sciences of the United States of America. 90. 2060-2064.
17. Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C., Gsur, A., Jager, U., Heinz, R., Lechner, K., Ludwig, H. & Huber, H. (1995) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescent in-situ hybridisation. Cancer Research. 55, 3854-3859.
18. Duperray, C., Bataille, R., Boiron, J.M., Haagen, I.A., Cantaloube, J.F., Zhan, X.G., Boucheix, C. & Klein, B. (1991) No expansion of pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma. Cancer Research, 51, 3224-3228.
19. Elomaa, I., Virkkunen, P., Risteli, L. & Risteli, J. (1992) Serum concentration of the cross linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful prognostic indicator in multiple myeloma. British Journal of Cancer, 66, 337-341.
20. Flactif, M., Zandecki, M., Lai, J.L., Bernardi, F., Obein, V., Bauters, F. & Facon, T. (1995) Interphase fluorescent in-situ hybridisation (FISH) as a powerful tool in the detection of aneuploidy in multiple myeloma. Leukemia. 9, 2109-2114.
21. Garcia-Sanz, R., Orfao, A., Gonzaalez, M., Moro, M.J., Hernaadez, J.M., Ortega, F., Borrego, D., Carnero, M., Cassnova, F., Jimenez, R., Portero, J.A. & San Miguel, J.F. (1995) Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. British Journal of Haematology. 90., 106-112.
22. 1 in the control of apoptosis in murine myeloma cells. Cancer Research, 56, 1451-1456.
23. Greipp, P.R., Katzman, J.A., O'Fallon, W.M. & Kyle, R.A. (1988) Value of β2 microglobulin level and plasma cell labelling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 72, 219-223.
24. Greipp, P.R., Lust, J.A., O'Fallon, W.M., Katzman, J.A., Witzig, T.E. & Kyle, R.A. (1993) Plasma cell labelling index and β2 microglobulin predict survival independent of thymidine kinase and C reactive protein in multiple myeloma. Blood, 81, 3382-3387.
25. Iida, S., Butler, M., Rao, P., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R.S.K. & Dalla-Favera, R. (1996) MUM1/ISCAT, a member of the interferon regulatory factor family (IRF), is involved in chromosomal translocations in multiple myeloma. Blood, 88. (Suppl. 1), 450a.
26. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwao, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83-85.
27. Kawano, M.M., Mahmoud, M.S., Huang, N., Lisukov, I.A., Mihara, K., Tsujimoto, T. & Kuramoto, A. (1995) High proportion of VLA-5-immature myeloma cells correlated well with poor response to treatment in multiple myeloma. British Journal of Haematology, 92, 860-864.
28. Klein, B., Widjenes, J., Zhang, X.G., Jourdan, M., Boiron, J.M., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z.Y., Mannoni, P., Sany, J. & Bataille, R. (1991) Marine antiinterleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 78, 1198-1204.
29. Klein, B., Zhang, X.G., Jourdan, M., Content, G., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin 6. Blood, 73, 517.
30. Kyrtsonis, M.C., Dedoussis, G., Zervas, C., Perifanis, V., Baxevanis, C., Stamatelou, M. & Maniatis, A. (1996) Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. British Journal of Haematology. 93, 398-400.
31. Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P. & Elomaa, K. (1992) Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet. 340, 1049-1052.
32. Lai, J.L., Zandecki, M., Mary, J.Y., Bernardi, F., Izydorczyk, V., Flactif, M., Morel, P., Jouet, J.P., Bauters, F. & Facon, T. (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood, 85, 2490-2497.
33. Lecouvet, F., vande Berg, B., Michaux, L., Labaisse, M.A., Ferrant, A., Malghem, J., Maldague, B. & Michaux, J.L. (1996) Magnetic resonance imaging of the bone marrow to assess the risk of disease progression in patients with monoclonal gammopathy of uncertain significance. British Journal of Haematology, 93, (Suppl. 2). 11-37.
34. Liang, W., Hopper, J.E. & Rowley, J.D. (1979) Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemias disorders. Cancer, 44, 630-644.
35. Lokhurst, H.M., Lamme, T., de Smet, M., Klein, S., de Weger, R.A., Van Oers, R. & Bloem, A.C. (1994) Primary tumor cells of myeloma patients induces IL-6 secretion in long term bone marrow cultures. Blood, 84, 2269-2277.
36. Manolagas, S.C. & Jilka, R.L. (1995) Bone marrow, cytokines and bone remodelling. New England Journal of Medicine, 332, 305-311.
37. Merlini, G., Perfetti, V., Gobbi, P.G., Quaglini, S., Franciotta, D.M., Marinone, G. & Ascari, E. (1993) Acute phase proteins and prognosis in multiple myeloma. British Journal of Haematology. 83, 595-601.
38. Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E. & Maiolo, A.T. (1993) P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 81, 128-135.
39. Ong, F., v. Nieuwkoop, J.A., de Groot-Swings, G.M.J.S., Hermans, J., Harvey, M.S., Kluin, P.H.M. & Kluin-Nelemaans, J.C. (1995) Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia, 9, 1282-1284.
40. Owen, R.G., Davis, S.A.A., Randerson, J., Rawstron, A.C., Davies, F.E., Child, I.A., Jack, A.S. & Morgan, G.J. (1997) P53 gene mutations in multiple myeloma. Journal of Clinical Pathology (Molecular Pathology). 50, 18-20.
41. Pecherstorfer, M., Seibel, M.J., Woitge, H.W., Schuster, J., Neuda, J., Horn, E., Bayer, P. & Ludwig, H. (1996) Diagnostic validity of urinary pyridinium crosslinks of collagen in the differentiation of multiple myeloma from monoclonal gammopathy of unknown significance and osteoporosis. British Journal of Haematology 93, (Suppl. 2). 497.
42. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M.J., Haarousseau, J.L., Bataille, R. & Amiot, M. (1995) Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumour spread and immortilisation. Cancer Research, 55, 3647-3653.
43. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J.L., Rapp, M.J., Juge-Morineau, N., Wijdenes, J. & Amiot, M. (1994) Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood, 84, 2597-2603.
44. Pelliniemi, T.T., Hirvonen, H., Laakso, M., Lahtinen, R., Leino, A., Rajamaki, A., Tienhaara, A. & Pulkki, K. (1996) High ratio of serum soluble interleukin 6 receptor (sIL-6R) to soluble glycoprotein 130 (sgp130) at diagnosis predicts poor prognosis in multiple myeloma. British Journal of Haematology. 93, (Suppl. 2), 619.
45. Pelliniemi, T.T., Irjala, K., Mattila, K., Pulkki, K., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1995) Immunoreactive interleukin 6 and acute phase proteins as prognostic factors in multiple myeloma. Blood. 85, 765-771.
46. Philip, P., Drivsholm, A., Hansen, N.E., Jenson, M.K. & Kilman, S.A. (1980) Chromosomes and survival in multiple myeloma: a banding study of 25 cases. Cancer, Genetics and Cytogenetics. 2, 243-257.
47. Portier, M., Moles, J.P., Makars, G.R., Jeantur, P., Bataille, R., Kleim, B. & Theillet, C. (1992) P53 and RAS gene mutations in multiple myeloma. Oncogene. 7, 2539-2543.
48. Preudhomme, C., Facon, T., Zaanddecki, M., Vanrumbeke, M., Lai, J., Nataf, E., Loucheux-Lefebvre, M.H., Kerckaert, J.P. & Fenaux, P. (1992) Rare occurrence of p53 gene mutations in multiple myeloma. British Journal of Haematology. 81, 440-443.
49. Pulkki, K., Pelliniemi, T.T., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology, 92, 370-374.
50. Rawstron, A.C., Davies, F.E., Owen, R.G., Johnson, R.J., Child, J.A., Jack, A.S. & Morgan, G.J. (1997a) B lymphocyte suppression in multiple myeloma: a reversible phenomenon specifically affecting B progenitor cells and normal plasma cell precursors. British Journal of Haematology, 97, (Suppl. 1), 2.
51. Rawstron, A.C., Owen, R.G., Davies, F.E., Johnson, R.J., Jones, R.A., Richards, S.J., Evans, P.A., Child, J.A., Smith, G.M., Jack, A.S. & Morgan, G.J. (1997b) Circulating plasma cells in multiple myeloma: characterization and correlation with disease status. British Journal of Haematology, 97, 46-55.
52. Rettig, M.B., Ma, H.J., Vescio, R.A., Pold, M., Schiller, G., Belson, D., Savage, A., Nishikubo, C., Wu, C., Fraser, J., Said, J.W. & Berenson, J.R. (1997) Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science, 276, 1851-1854.
53. Sangfeit, O., Osterborg, A., Grander, D., Anderbring, E., Ost, A., Mellstedt, H. & Einhorn, S. (1995) Response to Interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. International Journal of Cancer. 63, 190-192.
54. Sahota, S.S., Leo, R., Hamblin, T. & Stevenson, F. (1996) Ig Vh gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood. 87, 746-755.
55. Sawyer, J.R., Waldron, J.A., Jaganath, S. & Barlogie, B. (1995) Cytogenetics findings in 200 patients with multiple myeloma. Cancer, Genetics and Cytogenetics. 82, 41-49.
56. Smadja, V., Fruchart, C., Dutel, J.L., Isnard, F., Grange, M.J., Monconduit, M. & Bastard, C. (1996) Multiple myeloma: cytogenetic classification. British Journal of Haematology 93, (Suppl. 2), 502.
57. Smadja, V., Louvet, C., Isnard, F., Dutel, J.L., Grange, M.J., Varette, C. & Krulik, M. (1995) Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. British Journal of Haematology. 90, 619-624.
58. + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient specific VDJ rearrangements. Blood. 89, 1824-1833.
59. Tabernero, D., San Miguel, J.F., Garcia-Sanz, R., Najera, L., Garcia-Isidoro, M., Perez-Simon, J.A., Gonzalez, M., Wiegant, J., Raap, A.K. & Orfao, A. (1996) Incidence of chromosome numerical changes in multiple myeloma. American Journal of Pathology. 149, 153-161.
60. Taube, T., Beneton, M.N., McCloskey, E.V., Rogers, S., Greaves, M. & Kanis, J.A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology 49, 192-198.
61. Tienhaara, A. & Pelliniemi, T.T. (1994) Peripheral blood B lymphocytes in multiple myeloma. Acta Haematologica. 91, 57-61.
62. Tricot, G., Barlogie, B., Jaganath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S. & Sawyer, J. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 86, 4250-4256.
63. Tsuchiya, H., Epstein, J., Selvanayagam, P., Dedman, J.R., Gallick, G., Alexanian, R. & Barlogie, B. (1988) Correlated flow cytometric analysis of H ras p21 and nuclear DNA in multiple myeloma. Blood. 72, 796-800.
64. Tu, Y., Xu, F., Liu, J., Vescio, R., Berenson, J., Fady, C. & Lichtenstein, A. (1996) Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood, 88, 1805-1812.
65. Urashima, M., Chaauhan, D., Uchiyma, H., Freeman, G.J. & Anderson, K.C. (1995) CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 85, 1903-1912.
66. Van Camp, B., Durie, B.G.M., Spier, C., De Waele, M., Van Riet, I., Vela, E., Frutiger, Y., Ritcher, L. & Grogan, T. (1990) Plasma cells in multiple myeloma express a natural killer cell associated antigen: CD56. Blood. 76, 377-382.
67. Weh, H.J., Gutensohn, K., Selbaach, J., Kruse, R., WackerBaackhaus, G., Seeger, D., Fiedler, W., Fett, W. & Hossfeld, D.K. (1993) Karyotype in multiple myeloma and plasma cell leukaemia. European Journal of Cancer. 29A, 1269-1273.
68. Witzig, T.E., Gertz, M.A., Lust, J.A., Kyle, R., O'Fallon, W.M. & Griepp, P.R. (1996) Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 88, 1780-1787.
69. Zhang, X.G., Bataille, R., Widjenes, J. & Klein, B. (1992) Interleukin 6 dependence of advanced malignant plasma cell dyscrasias. Cancer. 69, 1373-1376.